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Abstract
Background
Age-related macular degeneration (AMD) shares many similarities with cardiovascular dis-
ease (CVD) pathophysiology. We sought to determine the relationship of AMD to the pro-
gression of coronary artery calcium (CAC) using data from the Multi-Ethnic Study of
Atherosclerosis (MESA).
Methods
Our cohort consisted of 5803 adults aged 45 to 84 years free of known cardiovascular dis-
ease (CVD). Retinal photographs were taken during visit 2 (Aug 2002-Jan 2004). CAC was
measured with computed tomography at visit 1 (July 2000-Aug 2002) and visit 5 (April 2010-
Dec 2011) and changes between visits were determined.
Results
Participants were categorized as with (n = 244) and without AMD (n = 5559) at visit 2. At
visit 5, 92 participants with and 2684 without AMD had CAC scores. Among those with
detectable CAC at baseline (>0 at visit 1), CAC progression was greater in persons with
compared to those without AMD after multivariable adjustment (530 ± 537 vs. 339 ± 426
Agatston units, P<0.01).
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Conclusions
The presence of AMD in a diverse population without known clinical CVD independently pre-
dicted higher 10-year CAC progression in participants with baseline CAC >0. The retinal
exam might be a useful tool for pre-clinical assessment and prevention of CVD events.
Introduction
Age-related macular degeneration (AMD) is a leading cause of vision loss in the US [1]. It is
estimated it will affect 288 million adults by 2040 [2]. The presence of AMD is associated with
various traditional cardiovascular disease (CVD) risk factors, including age [3], hypercholes-
terolemia [4], hypertension [5], and cigarette smoking [6], suggesting that the pathophysiology
of AMD and atherosclerotic CVD may be similar [7]. Additionally, AMD has been reported to
be associated with increased risk of stroke [8,9],coronary heart disease (CHD) [10] and all-
cause mortality [11]. Data from population-based studies evaluating AMD as a risk indicator
for cardiovascular events independent of traditional CVD risk factors have been inconsistent
[12,13,14,15,16]. Non-invasive cardiovascular testing and imaging techniques, such as coro-
nary artery calcium (CAC), are indicators of subclinical atherosclerosis. These indicators have
been associated with higher risk for future CVD events and have been suggested as surrogate
measures of CVD [17,18]. Thus, the objective of this study was to determine the association of
AMD with the progression of CAC as a subclinical CVD marker and whether any observed
relationship was independent of traditional CVD risk factors in a healthy, diverse population
participating in the Multi-Ethnic Study of Atherosclerosis (MESA). We hypothesized that the
presence of AMD would predict the progression of CAC.
Materials and methods
Participants and study design
The MESA is a prospective longitudinal study with the purpose of identifying risk factors for
subclinical CVD and its progression to clinical events [19]. The MESA cohort consists of a
diverse population sample of 6814 men and women aged 45 to 84 years at baseline (Exam 1;
July 2000 to July 2002) who were recruited from 6 field centers: Baltimore, MD; Chicago, IL;
Forsyth County, NC; Los Angeles, CA; New York, NY; and St. Paul, MN. Individuals with a
known history of CVD at baseline were excluded. Known history of CVD included myocardial
infarction, angina, heart failure, stroke, or transient ischemic attack or the following proce-
dures: coronary artery bypass graft, angioplasty, or other vascular surgeries. The cohort for the
present investigation consisted of adults free of known CVD who underwent retinal photogra-
phy during the first follow-up examination (Exam 2) conducted from August 2002 to January
2004. The tenets of the Declaration of Helsinki were adhered to, and each participating field
center was granted all necessary institutional review board approvals. Written informed con-
sent was obtained from each participant. This study was registered at clinicaltrials.gov as
NCT00005487.
Retinal examination
Retinal photography was performed using a standardized protocol [20]. Both eyes of each par-
ticipant were photographed using a 45˚, 6.3-megapixel digital non-mydriatic camera (Canon,
Lake Success, NY). Two photographic fields were taken of each eye, the first centered on the
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optic disc and the second centered on the fovea. The macula area was graded at the University
of Wisconsin Ocular Epidemiology Research Center for AMD features using a standard AMD
grading protocol [20]. Features of AMD included drusen size, type, and area; increased retinal
pigment; retinal pigment epithelial depigmentation; pure geographic atrophy; and signs of
exudative macular degeneration (subretinal hemorrhage, subretinal fibrous scar, retinal pig-
ment epithelial detachment, and/or serous detachment of the sensory retina or laser or photo-
dynamic treatment of for neovascular AMD). Graders were masked with respect to
information about the participant and each retinal image was graded twice (preliminary and
detail grading) using a modification of the Wisconsin Age-Related Maculopathy Grading
scheme [21].
Early AMD was defined by: 1) either the presence of any soft drusen (distinct or indistinct)
and pigmentary abnormalities (either increased retinal pigment or retinal pigment epithelium
depigmentation); or 2) the presence of a large soft drusen125 μm in diameter with a large
drusen area (>500 μm in diameter circle); or 3) large (125 μm in diameter) soft indistinct
drusen. Late AMD was defined by the presence of geographic atrophy or retinal pigment epi-
thelial detachment, subretinal hemorrhage or visible subretinal new vessels, or subretinal
fibrous scar or laser treatment scar for AMD. Any AMD was defined by the presence of early
or late AMD [22].
Coronary artery calcium
Acquisition, interpretation and measurement variance of CAC scans have been reported previ-
ously [23,24]. In the present study, our sample for incident CAC and CAC progression only
included participants who had CAC measured at both baseline and Exam 5 (April 2010-
December 2011). Incident CAC was defined as a baseline calcium score of 0 (zero) and avail-
able repeat CAC score > 0. Progression of CAC was determined for those participants with
baseline CAC scores greater than 0 (zero) and available repeat CAC whose score was higher
than the participant’s baseline value. Any increments from the baseline CAC score were con-
sidered progression of CAC.
Statistical analyses
Data are means ± SD or proportions for continuous and categorical variables, respectively,
with the exception of baseline CAC score which is presented as median [IQR]. After age
adjustment, means were compared via linear regression, categorical variables via logistic
regression (with AMD as the endpoint), and medians using quantile regression. Demographic
variables, CVD risk factors, and CAC at baseline were compared between AMD groups using
one-way analysis of variance (ANOVA) or χ2 tests. Among the participants with positive CAC
at baseline, robust linear regression coefficients and corresponding 95% confidence intervals
were estimated to compare the progression of CAC between the group of participants with
AMD and without AMD, adjusting for age, gender, race, level of education, systolic blood
pressure, hypertension medication, lipid lowering medication, smoking status, diabetic status,
serum total cholesterol, HDL cholesterol, and C-reactive protein.
Results
Of the 6176 participants who had retinal photographs acquired, 5874 (95%) had images grad-
able for AMD (Fig 1). Excluding those with CVD events prior to the first follow-up visit, our
cohort consisted of 5803 participants at baseline (S1 Table). Of these, 219 persons (3.8%) had
early AMD and 25 (0.4%) had late AMD. Thus, the presence of any AMD was detected at base-
line in 244 (4.2%) participants, while 5559 persons were categorized as no AMD (S1 Table).
Macular degeneration and coronary artery calcium
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Of the 2955 participants who had CAC measured at both baseline and Exam 5, 92 and 2863
were categorized as with and without AMD, respectively (Table 1). CAC scores were signifi-
cantly greater in participants who had AMD at baseline (median 143.1 [IQR 20.6, 384.2] versus
57.7 [15.2, 196.0] Agatston units; age-adjusted P-value = 0.021). There were 1170 (40.9%) and
46 (50%) participants with detectable CAC (CAC>0) at baseline in the group without AMD
and with AMD (P>0.05), respectively (S1 Table). There was no difference in the 10-year inci-
dence of the development of CAC as a function of AMD status (Table 2). After multivariable
adjustment, and in participants with baseline CAC>0, 10-year CAC progression was greater
in the participants with AMD compared to participants without AMD (P<0.01) (Table 2). In
Fig 1. Flow diagram describing the studied cohort.
https://doi.org/10.1371/journal.pone.0201000.g001
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participants with baseline CAC>0, 10-year CAC progression was greater in participants with
early AMD (n = 39) compared to participants without AMD (n = 1170) (P = 0.018) (Table 3).
Differences in the progression of CAC between types of AMD (early vs. late) could not be
Table 1. Baseline characteristics from participants with data on AMD who had CAC measured at both baseline (Exam 1) and Exam 5.
Characteristics Overall Cohort
(n = 2955)#
No AMD
(n = 2863)#
Any AMD
(n = 92)#
Total n
Age, years 59.6 (9.2) 59.3 (9.1) 66.4 (9.4) 2955
Male, n (%) 1379 (46.7) 1332 (46.5) 47 (51.1) 2955
Race
Caucasian, n (%) 1148 (38.8) 1103 (38.5) 45 (48.9) 2955
Chinese, n (%) 349 (11.8) 340 (11.9) 9 (9.8)
African Americans, n (%) 801 (27.1) 787 (27.5) 14 (15.2)
Hispanics, n (%) 657 (22.2) 633 (22.1) 24 (26.1)
High school graduate, n (%) 2552 (86.5) 2480 (86.7) 72 (79.1) 2950
Total cholesterol mg/dL 194.2 (34.9) 194.3 (35.0) 192.1 (32.8) 2947
HDL cholesterol mg/dL 51.0 (14.7) 50.9 (14.7) 53.4 (16.4) 2944
Hypertension medication, n (%) 997 (33.8) 964 (33.7) 33 (35.9) 2954
Lipid lowering medication, n (%) 448 (15.2) 433 (15.1) 15 (16.3) 2954
Diabetics, n (%) 271 (9.2) 262 (9.2) 9 (9.8) 2948
Former smokers, n (%) 1057 (35.8) 1021 (35.7) 36 (39.6) 2950
Current smokers, n (%) 355 (12.0) 345 (12.1) 10 (11.0) 2950
CAC = 0, n (%) 1739 (58.8) 1693 (59.1) 46 (50.0) 2955
1–99, n (%) 750 (25.4) 730 (25.5) 20 (21.7)
100–399, n (%) 306 (10.4) 290 (10.1) 16 (17.4)
400, n (%) 160 (5.4) 150 (5.2) 10 (10.9)
CAC score among those CAC>0, median (IQR) 58.6 (15.4, 200.7) 57.7 (15.2, 196.0) 143.1 (20.6, 384.2) 1216
Data are means (SD) or proportions unless otherwise indicated. Abbreviations: AMD = age-related macular degeneration; CAC = coronary artery calcium;
IQR = interquartile range.
#Sample size when there is no missing data.
All tests controlled for age, with
 indicating significance at the p<0.05 level.
https://doi.org/10.1371/journal.pone.0201000.t001
Table 2. Ten-year CAC progression by baseline AMD status (No AMD vs. Any AMD).
Baseline
CAC = 0
Incident CAC, n (%) Age, gender, time between CT scans adjusted OR (95% CI) Multivariable adjusted OR (95% CI)
No AMD
(n = 1693)
761 (45%) ref ref
Any AMD
(n = 46)
21 (46%) 0.71 (0.38, 1.31) 0.78 (0.42,1.47)
Baseline
CAC>0
Progression of CAC (CAC5-CAC1)
(mean ± SD)
Robust regression model, Age, gender, time between CT
scans adjusted (diff (se), p)
Multivariable robust regression model,
(diff (se), p)
No AMD
(n = 1170)
339 ± 426 ref ref
Any AMD
(n = 46)
530 ± 537 101 (40), 0.011 114 (39), 0.004
Abbreviations: AMD = age-related macular degeneration; CAC = coronary artery calcium.
adjusting for time between scans, age, gender, race, SBP, hypertension med, smoking status (never, former vs. current), total cholesterol, HDL cholesterol, lipid
lowering med, CRP, diabetic status and education (high school or higher).
https://doi.org/10.1371/journal.pone.0201000.t002
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ascertained due to limited power. Men and women had a similar association between AMD
and CAC progression (Fig 2).
Discussion
The present study demonstrates that the presence of AMD is associated with a greater 10-year
CAC progression after multi-variable adjustment in a diverse population. Our data suggest
that participants with AMD free of known clinical CVD with a CAC = 0 had no increase in the
incidence of CAC. Participants with a baseline CAC score>0 had greater CAC progression as
compared to those without AMD after a mean follow-up of 10.4 years in our cohort. This sub-
clinical progression was independent of traditional CVD risk factors. This finding is supported
by some [13,14,16,25,26], but not all [9,15,27], studies evaluating AMD and CVD/CHD
events.
There are few published studies evaluating the contribution of baseline AMD to the devel-
opment of clinical atherosclerotic CVD [13, 14,16,25,26,9,15,27]. An evaluation from the Ath-
erosclerosis Risk in Communities (ARIC) study dataset demonstrated that participants early
macular degeneration had a higher incident stroke hazard ratio (HR = 1.85, 95% CI, 1.19–
2.87) than individuals without AMD [9]. Individuals with late AMD were three times more
likely to have an incident coronary artery disease (CAD) event (RR = 3.05, 95% CI, 1.14–8.17
with a 10-year cumulative incidence, 30.9%) as compared to participants without late AMD
(10-year cumulative incidence, 10%) [16].This supports the notion that the more severe forms
of AMD might have an association with CAD events. In the Blue Mountain Eye Study partici-
pants younger than 75 years with baseline early AMD had a 2.26-fold increased risk of CAD
mortality when compared to age and sex matched controls [15]. Adjustments of relative risk
by serum lipid levels and hypertension treatment were not reported.
Our group found no increased risk of clinical CVD events in patients with baseline AMD
in a previous investigation also using the MESA dataset [14]. It is possible that the MESA
cohort design could explain the discrepancy found with the results from other cohorts. The
MESA participants had no clinical CVD and were likely healthier than those in other studies.
Table 3. Ten-year CAC progression by baseline AMD status (No AMD vs. Early/Late AMD).
Baseline
CAC = 0
Incident CAC, n
(%)
Age, gender, time between CT scans adjusted OR (95% CI) Multivariable adjusted OR (95% CI)
No AMD
(n = 1693)
761 (45%) ref ref
AMD early
(n = 44)
20 (45%) 0.70 (0.38, 1.31) 0.78 (0.41, 1.48)
AMD late (n = 2) 1 (50%) 0.69 (0.04, 11.60) 0.84 (0.05, 15.01)
Baseline CAC>0 Progression of
CAC
(CAC5-CAC1)
(mean ± SD)
Robust regression model, Age, gender, time between CT scans
adjusted(diff (SE), p-value)
Multivariable robust regression model,(diff
(SE), p-value)
No AMD
(n = 1170)
339 ± 426 ref ref
AMD early
(n = 39)
529 ± 532 102 (43), 0.018 116 (42), 0.006
AMD late (n = 7) 539 ± 607 99 (99), 0.319 104 (97), 0.283
Abbreviations: AMD = age-related macular degeneration; CAC = coronary artery calcium.
adjusting for time between scans, age, gender, race, SBP, hypertension med, smoking status (never, former vs. current), total cholesterol, HDL cholesterol, lipid
lowering med, CRP, diabetic status.
https://doi.org/10.1371/journal.pone.0201000.t003
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Therefore, our current hypothesis sought to determine whether differential patterns of sub-
clinical CVD, as measured by CAC scores changes, exist in our cohort. To our knowledge, this
is the first study correlating baseline AMD and CAC progression.
CAC scores have been evaluated for their contribution to CVD risk prediction. The 2013
American College of Cardiology/American Heart Association cholesterol guidelines intro-
duced the use of the new risk prediction Pool Cohort Equation and CAC to improve athero-
sclerotic CVD risk prediction and risk-based treatment strategies in primary CVD prevention
[28]. Data from the MESA showed that CAC independently predicted CVD events and
improves risk discrimination over and beyond the Pool Cohort Equation and the traditional
Framingham risk equation enhancing CVD risk prediction [29,30].
Progression of vascular calcification has the potential to better capture the temporal expo-
sure to risk factors compared with a single baseline score. It has been suggested that a baseline
CAC can be thought of as a single point on an atherosclerosis-versus-time curve, whereas pro-
gression correlated with the slope of that curve [31]. Baseline scores might reflect atheroscle-
rotic plaque burden, whereas progression might provide insight into ongoing current disease
activity. Rapid progression of CAC is independently predictive of mortality [32].
3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors or “statins” can
stabilized coronary artery plaques by increasing its calcium composition and this relationship
Fig 2. Change in CAC score between Exam 2 and Exam 5 by AMD status and sex. CAC = coronary artery calcium; AMD = age-related macular
degeneration.
https://doi.org/10.1371/journal.pone.0201000.g002
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could have an inverse relationship with CVD events [17]. This paradoxical finding is presumed
to be a healing phenomenon that occurs when lipid is removed from the arterial wall, resulting
in more calcium deposition. It is possible that in our study, the increase in CAC progression in
the AMD group was due to increased statin use. In our cohort, the prevalence of lipid-lowering
medication use was higher in participants with (16.4%) versus without AMD (15.7%). None-
theless, some of the participants not on lipid-lowering agents at baseline were prescribed these
medications during follow-up. The two-time point design of our CAC progression model did
not allow incorporating new statin use as a time-varying covariate. Thus, it is possible that our
findings could reflect a closer medical care (including greater statin use) of the AMD group
and statin-induced CAC progression denoting more calcified but stable plaque burden.
Another limitation of our study includes the failure to capture a larger proportion of indi-
viduals with AMD. The MESA participants had no clinical CVD and were likely healthier than
those in other studies. This could explain the lower proportion of AMD participants in our
cohort and the discrepancy found with our previous investigation of clinical outcomes and the
results from other cohorts. Lastly, the AMD assessment was made at visit 2 of the MESA
(August 2001-January 2004) but the baseline CAC was measured at visit 1 (July 2000-August
2002). This difference in the timing of baseline measures may have impacted our incidence
analysis as it is possible that CAC may have developed between visits 1 and 2. In conclusion,
the association of AMD with 10-year CAC progression in the MESA suggests a greater pro-
gression of CVD. Our study adds to the previous conflicting reports regarding the clinical
importance of AMD in CVD prediction [12,13,14,15,16], and supports the notion that AMD
may be a local manifestation of systemic processes and not confined to the deeper layers of the
retina [33]. The higher progression of CAC in the AMD group suggests that AMD might be a
player in the progression subclinical CVD which could be important for clinicians who employ
serial screening techniques to assess changes in risk or progressive disease states. A retinal
exam might be a useful tool for pre-clinical assessment of microvascular processes that under-
lie the development of CVD. In patients already diagnosed with AMD, communication
between the internist, an ophthalmologist and potentially a cardiologist might be beneficial
when managing the care of each condition. However, our finding has not correlated with clini-
cal outcomes in our cohort yet. The clinical evidence linking AMD and CAD remains incon-
clusive and firm recommendations should await the results of dedicated clinical outcomes
studies in patients with AMD.
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